Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$890.68 USD
-15.86 (-1.75%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $886.00 -4.68 (-0.53%) 5:04 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
REGN 890.68 -15.86(-1.75%)
Will REGN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for REGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for REGN
EXEL vs. REGN: Which Stock Is the Better Value Option?
Intellia (NTLA) to Report Q1 Earnings: What's in the Cards?
REGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up
Regeneron (REGN) Reports Next Week: What You Should Expect
The Zacks Analyst Blog Highlights Danaher, Regeneron Pharmaceuticals, Palo Alto Networks, Workday and American Electric Power
Other News for REGN
AbbVie reports positive results from Rinvoq versus Dupixent study
Regeneron, Mammoth in pact to develop CRISPR-based gene editing therapies
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases
Regeneron, Mammoth collaborate to purse next-generation gene editing
Wells Fargo Reaffirms Their Buy Rating on Regeneron (REGN)